Core Viewpoint - The major shareholder of Zhongwei Semiconductor Equipment (Shanghai) Co., Ltd. plans to reduce its stake through block trading while the company is also planning to issue shares to acquire assets and raise matching funds, leading to a temporary suspension of its stock trading [1][9]. Shareholder Information - As of the announcement date, Shanghai Chuangtou holds 93,483,533 shares of Zhongwei, accounting for 14.93% of the total share capital [2]. Reduction Plan Progress - On December 1, 2025, the company announced that Shanghai Chuangtou plans to reduce its holdings by up to 1% of the total share capital, which is 6,261,453 shares, within three months after the 15 trading days following the announcement [3]. - As of December 18, 2025, the reduction period has not yet started, and the plan has not been implemented due to the company's ongoing asset acquisition and fundraising plans [4]. Impact of Reduction Plan - The implementation of the reduction plan will not lead to a change in the company's controlling interest and will not affect the company's governance structure, shareholding structure, or ongoing operations [6]. Trading Suspension - The company's stock will be suspended from trading starting December 19, 2025, due to the planned issuance of shares to acquire the controlling interest in Hangzhou Zhonggui Electronics Technology Co., Ltd. [11]. - The suspension is expected to last no more than 10 trading days, and the company will disclose further information as the situation progresses [11]. Transaction Details - The transaction involves acquiring the controlling interest in Hangzhou Zhonggui, which specializes in the research, production, and sales of high-end Chemical Mechanical Polishing (CMP) equipment [12]. - The company aims to strengthen its core technology and provide more competitive integrated process solutions through this acquisition, marking a significant step towards a "group" and "platform" strategy [15][16].

Group 1 - The company, Aorite Pharmaceutical Co., Ltd., has received a GMP compliance inspection notice from the Zhejiang Provincial Drug Administration, confirming that its production lines meet the required standards [1] - The inspection covered the production of active pharmaceutical ingredients, specifically mometasone furoate and betamethasone, conducted from November 12 to November 14, 2025 [1] - The inspection concluded that the company complies with the relevant laws and regulations, including the Drug Administration Law and the Good Manufacturing Practice (GMP) guidelines [1] Group 2 - The company is expected to maintain stable product quality and production capacity, which will help meet market demand for its pharmaceutical products [3] - The company acknowledges that future sales may be influenced by market conditions and industry policies, indicating potential uncertainties in the pharmaceutical sector [3]

Core Viewpoint - The company has completed the registration of the first batch of shares under its 2023 restricted stock incentive plan, with a total of 383,603 shares set to be listed for trading on December 24, 2025 [4][10]. Group 1: Stock Listing and Incentive Plan - The stock listing type is for equity incentive shares, with a total of 383,603 shares to be listed [2][3]. - The shares will be available for trading starting December 24, 2025 [4][10]. - The company received the registration certificate from the China Securities Depository and Clearing Corporation on December 18, 2025, confirming the completion of the registration process for the first batch of shares under the incentive plan [4][16]. Group 2: Decision-Making Process and Approval - The company held its first board meeting on September 22, 2023, where it approved the draft of the 2023 restricted stock incentive plan and related proposals [5]. - The supervisory board also approved the relevant proposals on the same day [5]. - The company conducted a public announcement regarding the independent directors' solicitation of voting rights for the upcoming shareholder meeting on October 26, 2023 [6]. Group 3: Shareholder Meeting and Compliance - The first temporary shareholder meeting was held on November 10, 2023, where the incentive plan and related proposals were approved [6]. - A self-inspection report regarding insider trading was disclosed on November 11, 2023, confirming no violations were found [6]. Group 4: Stock Structure and Financial Impact - Following the share allocation, the total number of shares will increase from 401,841,572 to 402,225,175 [14]. - The new shares represent approximately 0.0955% of the total shares before the allocation and are not expected to significantly impact the company's financial results [17]. - The adjusted share price for the incentive plan was set at 26.73 yuan per share, down from 26.855 yuan [9].

附件 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 第二届董事会职工代表董事简历 根据《中华人民共和国公司法》（以下简称"《公司法》"）《上海证券交易所科创板上市公司自律监管 指引第1号一一规范运作》《上市公司章程指引（2025年修订）》等法律法规、规范性文件及《北京神 舟航天软件技术股份有限公司章程》（以下简称"《公司章程》"）的相关规定，北京神舟航天软件技术 股份有限公司（以下简称"公司"）董事会设职工代表董事1名。公司于2025年12月18日召开职工代表大 会，经民主讨论、表决，同意选举何清法先生为公司第二届董事会职工代表董事（简历详见附件），何 清法先生将与公司2025年第六次临时股东会选举产生的其他5名非独立董事、3名独立董事共同组成公司 第二届董事会，任期与第二届董事会任期一致。公司第二届董事会中兼任公司高级管理人员以及由职工 代表担任的董事人数总计不超过公司董事总数的二分之一。 截至本公告披露日，何清法先生未直接持有公司股份。何清法先生符合《公司法》《上海证券交易所科 创板股票上市规则》等相关法律法规及《公 ...

Meeting Overview - The shareholders' meeting was held on December 18, 2025, at the company's conference room in Tianjin [2] - The meeting was conducted with a combination of on-site and online voting, presided over by the company's president, as the chairman was absent [2][3] Attendance - Out of 9 current directors, 7 attended the meeting, while 3 supervisors were present [3] - Some directors and supervisors attended via video conference [4] Resolutions Passed - The following resolutions were approved: 1. Cancellation of the supervisory board [5] 2. Abolishment of the "Supervisory Meeting Rules" [5] 3. Change of business scope [6] 4. Revision of the company's articles of association [6] 5. Revision of certain governance systems [6] 6. Approval of estimated daily related party transaction limits for 2026 [6] 7. Approval of comprehensive credit limits and guarantees for wholly-owned subsidiaries for 2026 [6] 8. Appointment of the auditing firm for 2025 [6] Voting Results - Resolutions 4 and 7 were special resolutions, requiring more than two-thirds of the votes from present shareholders [7] - Resolutions 1, 2, 3, 5, 6, and 8 were ordinary resolutions, requiring more than half of the votes from present shareholders [7] - Related party transaction resolution involved a shareholder who abstained from voting [7] Legal Verification - The meeting was witnessed by Beijing Zhonglun Law Firm, confirming that the meeting's procedures complied with legal and regulatory requirements [7]

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 索通发展股份有限公司（以下简称"公司"或"索通发展"）于近期收到上海证券交易所上市公司管理一部 《关于索通发展股份有限公司境外投资相关董事会决议存在弃权票的监管工作函》（上证公函【2025】 4048号）（以下简称"《工作函》"）。公司收到《工作函》后高度重视，积极组织相关部门对《工作 函》所涉及问题进行全面核实和分析，现就《工作函》有关问题回复如下： 一、根据公告，公司先后在2023年6月、2025年5月披露与EGA公司签署《投资谅解备忘录》《联合开 发协议》，本次双方签署《合资协议》系投资进展。公司披露称，阳极生产厂的建设将于2026年第二/ 三季度开始，并在2028年第二/三季度末开始商业化生产，但未详细披露该投资项目的建设工期，以及 具体的经济效益等。 请公司补充披露：（1）阳极生产厂项目的后续建设安排，包括各项投资项目的金额、建设周期、资金 来源等；（2）阳极生产厂项目经营达成后预计效益的测算过程，包括但不限于预计实现的 ...

注：控股股东及一致行动人持股比例从64.48%被动变为62.69%。 一、股权激励计划前期基本情况 海利尔药业集团股份有限公司（以下简称"公司"）2025年限制性股票激励计划（以下简称"本次激励计 划"）方式为___限制性股票_，股份来源为_公司向激励对象定向发行公司A股普通股_，拟授予的权益 数量为_1,250.00万股__，占公司总股本比例为__3.68%____。其中，首次授予的权益数量为_1,150.00万 股_____，占公司总股本比例为__3.38%____；预留授予的权益数量为__100.00万股____，占公司总股本 比例为__0.29%____。具体内容详见公司2025年9月30日披露于上海证券交易所官网（www.sse.com.cn） 的《海利尔药业集团股份有限公司2025年限制性股票激励计划（草案）摘要公告》（公告编号：2025- 048）。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ■ 二、限制性股票授予情况 （一）本次权益授予的具体情况 ■ 5、股票来源：公司向激励对象定向发行本 ...

一般项目：家具制造;家具零配件生产;家具销售;家具零配件销售;家具安装和维修服务;木材加工;人造板 制造;地板制造;楼梯制造;建筑用木料及木材组件加工;门窗制造加工;门窗销售;室内木门窗安装服务;金属 门窗工程施工;卫生洁具制造;卫生洁具销售;卫生洁具研发;卫生陶瓷制品制造;卫生陶瓷制品销售;厨具卫 具及日用杂品批发;厨具卫具及日用杂品零售;厨具卫具及日用杂品研发;玻璃制造;日用玻璃制品制造;日 用玻璃制品销售;家居用品制造;家居用品销售;日用杂品制造;五金产品制造;五金产品批发;五金产品零售; 五金产品研发;家用纺织制成品制造;家用电器制造;家用电器销售;家用电器研发;家用电器零配件销售;家 用电器安装服务;照明器具制造;照明器具销售;日用百货销售;建筑装饰材料销售;运输货物打包服务;普通 货物仓储服务（不含危险化学品等需许可审批的项目）;国内货物运输代理;装卸搬运;专业设计服务;工 业设计服务;工业工程设计服务;软件开发;软件销售;互联网销售（除销售需要许可的商品）;货物进出口; 技术进出口 ■ 二、欧派集成本次变更后的工商登记信息情况 欧派集成换发后的《营业执照》登记的主要信息如下： 1、名称：广州欧派 ...

Core Viewpoint - Ningbo Meinuohua Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the raw material drug Atorvastatin Calcium, which will enhance the company's product line and business scope [1][3]. Group 1: Registration Information - The registration number for Atorvastatin Calcium is Y20240000440, and it is produced by Xuancheng Meinuohua Pharmaceutical Co., Ltd. in Anhui [1]. - The product is available in various packaging specifications: 5kg, 10kg, 15kg, 20kg, and 25kg [1]. - The approval indicates that the product meets the requirements for drug registration under the Drug Administration Law of the People's Republic of China [1]. Group 2: Indications and Pharmacological Action - Atorvastatin Calcium is indicated for the treatment of hypercholesterolemia and mixed hyperlipidemia, as well as for the prevention and treatment of coronary heart disease [2]. - The drug functions as a statin, primarily acting in the liver to reduce cholesterol synthesis, increase low-density lipoprotein receptor synthesis, lower blood cholesterol and low-density lipoprotein cholesterol levels, moderately decrease serum triglyceride levels, and increase high-density lipoprotein levels [2]. Group 3: Impact on the Company - Xuancheng Meinuohua submitted the review application for Atorvastatin Calcium on May 16, 2024, and it passed the review on December 17, 2025, with a cumulative R&D investment of 14.9496 million yuan [3]. - The approval of Atorvastatin Calcium demonstrates compliance with national drug review technical standards, allowing the product to be sold in the domestic market, which will enrich the subsidiary's product line and help expand the company's business scope [3].

Group 1 - The court will conduct a public auction for 10,470,610 shares of Jiangxi Mubang High-Tech Co., Ltd. (stock code: 603398) held by Jiangxi Mubang New Energy Holdings Co., Ltd. on January 26-27, 2026 [1] - The starting price for the auction is set at 76,058,511.04 yuan, calculated as 80% of the average closing price over the last 20 trading days prior to December 16, 2025, multiplied by the total number of shares [1] - A deposit of 7,605,851 yuan is required to participate in the auction, with a minimum bid increment of 380,292 yuan [1] Group 2 - Legal and regulatory restrictions prevent certain entities from participating in the auction, including those prohibited from holding or trading shares of listed companies [2] - Bidders and their concerted actions must not exceed 30% of the total issued shares of the company; if they do, they must comply with relevant securities laws and report to the court [2]